Letter: reduction in chronic hepatitis B-related hepatocellular carcinoma with anti-viral therapy, including low-risk patients - more questions than answers. Authors' reply
Aliment Pharmacol Ther
.
2017 Jan;45(1):186-187.
doi: 10.1111/apt.13859.
Authors
D Lin
1
,
H-I Yang
2
,
J Hoang
3
,
M H Nguyen
3
Affiliations
1
Department of Medicine, Stanford University Medical Center, Palo Alto, CA, USA.
2
Genomics Research Center, Academia Sinica, Taipei, Taiwan.
3
Division of GI and Hepatology, Stanford University Medical Center, Palo Alto, CA, USA.
PMID:
27910142
DOI:
10.1111/apt.13859
No abstract available
Publication types
Letter
Comment
MeSH terms
Antiviral Agents
Carcinoma, Hepatocellular*
Hepatitis B, Chronic*
Humans
Liver Neoplasms
Substances
Antiviral Agents